Currently, there are 97.41M common shares owned by the public and among those 67.38M shares have been available to trade.
The company’s stock has a 5-day price change of -0.11% and 216.33% over the past three months. PSTX shares are trading 182.44% year to date (YTD), with the 12-month market performance up to 182.44% higher. It has a 12-month low price of $1.87 and touched a high of $9.58 over the same period. PSTX has an average intraday trading volume of 1.22 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 0.71%, 75.68%, and 168.63% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Poseida Therapeutics Inc (NASDAQ: PSTX) shares accounts for 55.76% of the company’s 97.41M shares outstanding.
It has a market capitalization of $924.94M and a beta (3y monthly) value of 1.64. The earnings-per-share (ttm) stands at -$0.63. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.06% over the week and 1.32% over the month.
Earnings per share for the fiscal year are expected to increase by 48.40%, and -138.20% over the next financial year. EPS should grow at an annualized rate of 2.70% over the next five years, compared to -12.83% over the past 5-year period.
Looking at the support for the PSTX, a number of firms have released research notes about the stock. Piper Sandler stated their Neutral rating for the stock in a research note on December 02, 2024, with the firm’s price target at $10. H.C. Wainwright coverage for the Poseida Therapeutics Inc (PSTX) stock in a research note released on January 04, 2023 offered a Buy rating with a price target of $15. Cantor Fitzgerald was of a view on January 07, 2022 that the stock is Overweight, while BTIG Research gave the stock Buy rating on May 18, 2021, issuing a price target of $40. William Blair on their part issued Outperform rating on August 04, 2020.
